Monthly Archives: October 2012

However they were achieved, risk assessments have been the basis of decision-making around containment of potent compounds and segregation of products, e.g.sensitizers and oncolytics, since the 1980’s. This has driven  the pharmaceutical industry to great lengths and cost to prevent … Continue reading →

Evolution of Flexible Containment in the Pharmaceutical Industry and the role that FabOhio Inc. played. Before 1993 there was one publicly disclosed use of flexible barriers in pharmaceutical manufacturing. An iconic European supplier of rigid isolators had installed an entire … Continue reading →